Lustgarten Foundation Boosts Pancreatic Cancer Funding to $22.8 Million

The foundation’s strategy prioritizes a comprehensive look at the disease, dedicating 66% of its current 62 active grants to therapeutics development, while the remainder targets early interception and personalized biology. By funding clinical accelerators and interdisciplinary team science, the organization aims to bypass traditional research bottlenecks that often delay the translation of laboratory discoveries into human trials.

Key initiatives include the Dr. Robert F. Vizza Clinical Accelerator, which is currently funding trials for aggressive subtypes involving KRAS mutations and BRCA-related cancers. Beyond specific trials, the foundation is leveraging artificial intelligence through the LEAD project to improve clinical trial accessibility, ensuring that patient recruitment is both efficient and equitable. CEO Linda Tantawi noted that while the research landscape faces significant funding volatility, this expanded investment is intended to secure momentum for scientists working on the front lines of oncology. Since its inception in 1998, the foundation has now directed $333 million across 86 academic institutions to move pancreatic cancer toward a treatable, and eventually curable, condition.